Antimicrobial susceptibility of Mycobacterium avium complex mycobacteria isolated from patients in Ural Federal District of the Russian Federation

Q4 Medicine
T. Umpeleva, M. Shulgina, D. Vakhrusheva, N. Eremeeva
{"title":"Antimicrobial susceptibility of Mycobacterium avium complex mycobacteria isolated from patients in Ural Federal District of the Russian Federation","authors":"T. Umpeleva, M. Shulgina, D. Vakhrusheva, N. Eremeeva","doi":"10.36488/cmac.2022.2.147-154","DOIUrl":null,"url":null,"abstract":"Objective. To assess minimal inhibitory concentrations (MICs) of antimicrobials for Mycobacterium avium complex (MAC) mycobacteria isolated from patients in Ural Federal District of the Russian Federation. Materials and Methods. We determined MICs for 33 M. avium and 34 M. intracellulare strains isolated from 67 patients with mycobacteriosis or tuberculosis/mycobacteriosis co-infection during 2018– 2019. SLOMYCO Sensititre test-system was used for susceptibility testing to 12 antibiotics: amikacin, streptomycin, clarithromycin, ethambutol, rifabutin, rifampicin, ciprofloxacin, ethionamide, isoniazid, linezolid, moxifloxacin, and doxycycline. Mycobacteria isolates were categorized according to their MICs as “susceptible”, “susceptible with increased exposure to the drug”, and “resistant” using CLSI breakpoints (2018). Breakpoints for amikacin, clarithromycin, linezolid and moxifloxacin were available for M. avium complex, for ciprofloxacin, doxycycline, rifabutin, rifampicin – for slow growing nontuberculous mycobacteria other than MAC mycobacteria. Breakpoints for ethambutol, isoniazid, streptomycin and ethionamide were not available. Results. Rates of susceptibility of M. avium and M. intracellulare were: amikacin – 96.9% and 97.0%, clarithromycin – 84.8% and 97.1%, linezolid – 9.1% and 23.5%, moxifloxacin – 57.6% and 38.2%, respectively. Majority of M. avium and M. intracellulare isolates were resistant to ciprofloxacin, doxycycline, and rifampicin. Ethambutol MICs for 84.4% of M. avium and for 67.7% of M. intracellulare isolates were > 8 mg/L. The majority of studied isolates (64.2%) were susceptible to at least three antimicrobials for the treatment of infections caused by MAC mycobacteria. Conclusions. Macrolides and aminoglycosides were the most effective against MAC mycobacteria in our study. Use of macrolides in combination with rifabutin and amikacin or moxifloxacin and amikacin may increase treatment efficacy in infections caused by M. avium and M. intracellulare.","PeriodicalId":53392,"journal":{"name":"Klinicheskaia mikrobiologiia i antimikrobnaia khimioterapiia","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Klinicheskaia mikrobiologiia i antimikrobnaia khimioterapiia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36488/cmac.2022.2.147-154","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1

Abstract

Objective. To assess minimal inhibitory concentrations (MICs) of antimicrobials for Mycobacterium avium complex (MAC) mycobacteria isolated from patients in Ural Federal District of the Russian Federation. Materials and Methods. We determined MICs for 33 M. avium and 34 M. intracellulare strains isolated from 67 patients with mycobacteriosis or tuberculosis/mycobacteriosis co-infection during 2018– 2019. SLOMYCO Sensititre test-system was used for susceptibility testing to 12 antibiotics: amikacin, streptomycin, clarithromycin, ethambutol, rifabutin, rifampicin, ciprofloxacin, ethionamide, isoniazid, linezolid, moxifloxacin, and doxycycline. Mycobacteria isolates were categorized according to their MICs as “susceptible”, “susceptible with increased exposure to the drug”, and “resistant” using CLSI breakpoints (2018). Breakpoints for amikacin, clarithromycin, linezolid and moxifloxacin were available for M. avium complex, for ciprofloxacin, doxycycline, rifabutin, rifampicin – for slow growing nontuberculous mycobacteria other than MAC mycobacteria. Breakpoints for ethambutol, isoniazid, streptomycin and ethionamide were not available. Results. Rates of susceptibility of M. avium and M. intracellulare were: amikacin – 96.9% and 97.0%, clarithromycin – 84.8% and 97.1%, linezolid – 9.1% and 23.5%, moxifloxacin – 57.6% and 38.2%, respectively. Majority of M. avium and M. intracellulare isolates were resistant to ciprofloxacin, doxycycline, and rifampicin. Ethambutol MICs for 84.4% of M. avium and for 67.7% of M. intracellulare isolates were > 8 mg/L. The majority of studied isolates (64.2%) were susceptible to at least three antimicrobials for the treatment of infections caused by MAC mycobacteria. Conclusions. Macrolides and aminoglycosides were the most effective against MAC mycobacteria in our study. Use of macrolides in combination with rifabutin and amikacin or moxifloxacin and amikacin may increase treatment efficacy in infections caused by M. avium and M. intracellulare.
俄罗斯联邦乌拉尔联邦区患者分离的禽分枝杆菌复合分枝杆菌的抗菌敏感性
目标。评估抗微生物药物对俄罗斯联邦乌拉尔联邦区患者分离的鸟分枝杆菌复合体(MAC)分枝杆菌的最低抑制浓度(mic)。材料与方法。我们检测了2018 - 2019年67例分枝杆菌病或结核/分枝杆菌病合并感染患者中分离的33株鸟分枝杆菌和34株胞内分枝杆菌的mic。采用SLOMYCO Sensititre试验系统对阿米卡星、链霉素、克拉霉素、乙胺丁醇、利福平、利福平、环丙沙星、乙硫酰胺、异烟肼、利奈唑胺、莫西沙星、多西环素12种抗生素进行药敏试验。根据CLSI断点(2018年),分枝杆菌分离株根据其mic分类为“易感”、“易受药物暴露增加”和“耐药”。对于鸟分枝杆菌复合体,对于环丙沙星、多西环素、利福平、利福平,对于除MAC分枝杆菌以外生长缓慢的非结核分枝杆菌,阿米卡星、克拉霉素、利奈唑胺和莫西沙星的断点是可用的。结果鸟分枝杆菌和胞内分枝杆菌的敏感率分别为:阿米卡星96.9%和97.0%,克拉霉素84.8%和97.1%,利奈唑胺9.1%和23.5%,莫西沙星57.6%和38.2%。大多数鸟分枝杆菌和胞内分枝杆菌对环丙沙星、强力霉素和利福平耐药。乙胺丁醇对84.4%的鸟分枝杆菌和67.7%的胞内分枝杆菌的mic为8mg /L。大多数分离株(64.2%)对至少3种抗MAC分枝杆菌感染药物敏感。结论:大环内酯类药物和氨基糖苷类药物对MAC分枝杆菌最有效。大环内酯类药物与利福布汀和阿米卡星或莫西沙星和阿米卡星联合使用可提高由鸟分枝杆菌和胞内分枝杆菌引起的感染的治疗效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.90
自引率
0.00%
发文量
0
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信